Lyell Immunopharma
Stock Forecast, Prediction & Price Target
Lyell Immunopharma Financial Estimates
Lyell Immunopharma Revenue Estimates
Lyell Immunopharma EBITDA Estimates
Lyell Immunopharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $10.65M N/A | $84.68M 695.14% | $130K -99.84% | Avg: $3.33M Low: $3.33M High: $3.33M avg. 2464.1% | Avg: $315.36K Low: $315.36K High: $315.36K avg. -90.53% | ||
Net Income
% change YoY
| $-285.50M N/A | $-4.75M 98.33% | $-234.63M -4835.46% | Avg: $-253.14M Low: $-258.51M High: $-210.82M avg. -7.89% | Avg: $-334.24M Low: $-233.41M High: $-213.33M avg. -32.03% | ||
EBITDA
% change YoY
| $-164.70M N/A | $-165.09M -0.23% | $-226.75M -37.34% | Avg: $-3.33M Low: $-3.33M High: $-3.33M avg. 98.53% | Avg: $-315.36K Low: $-315.36K High: $-315.36K avg. 90.53% | ||
EPS
% change YoY
| -$1.18 N/A | -$0.02 98.37% | -$0.93 -4743.75% | Avg: -$0.91 Low: -$1.03 High: -$0.84 avg. 2.50% | Avg: -$0.89 Low: -$0.93 High: -$0.85 avg. 1.83% | ||
Operating Expenses
% change YoY
| $225.42M N/A | $276.49M 22.65% | $247.13M -10.61% | Avg: $393.75M Low: $393.75M High: $393.75M avg. 59.32% | Avg: $37.25M Low: $37.25M High: $37.25M avg. -90.53% | ||
FAQ
What is Lyell Immunopharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -19.96% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -258.51M, average is -253.14M and high is -210.82M.
What is Lyell Immunopharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1186.78% in 2025-2026.
We have gathered data from 2 analysts. Their low revenue estimate is $3.33M, average is $3.33M and high is $3.33M.
What is Lyell Immunopharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 2.17% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.03, average is -$0.91 and high is $-0.84.
What is the best performing analyst?
In the last twelve months analysts have been covering Lyell Immunopharma stock. The most successful analyst is Geoff Meacham.